諾和諾德
NVO55.620USD
+0.750+1.37%
收盤 09/15, 16:00（美東）報價延遲15分鐘
187.11B總市值
11.57本益比TTM
關於 諾和諾德 公司
諾和諾德是一家專注糖尿病護理的全球醫療健康公司，同時涉足藥物的發現、研發、生產與行銷。公司透過「糖尿病與肥胖護理」及「生物製藥」兩大業務運作。前者產品組合含胰島素、GLP-1 受體激動劑（Ozempic、Wegovy、Rybelsus 等） 、胰高血糖素等蛋白質類療法、蛋白質投遞系統與注射針頭，以及口服降糖藥；後者聚焦血友病護理、生長激素補充及激素替代治療。另有 Saxenda 專門針對臨床肥胖症。主要品牌包含 NovoLog/NovoRapid、NovoLog Mix/NovoMix、Prandin/NovoNorm、NovoSeven、Norditropin、Vagifem 等。公司藥品銷往逾一百八十個國家，全球商業體系由北美與國際運營兩大區域組成，透過臨床研究、製造網絡與市場渠道將療法帶給患者。
公司簡介
公司代碼NVO
公司名稱Novo Nordisk A/S
上市日期May 17, 1974
CEOMr. Maziar Mike Doustdar
員工數量76302
證券類型Ordinary Share
年結日May 17
公司地址Novo Alle 1
城市BAGSVAERD
上市交易所The Toronto Stock Exchange
國家Denmark
郵編2880
電話4544448888
網址https://www.novonordisk.com/
公司代碼NVO
上市日期May 17, 1974
CEOMr. Maziar Mike Doustdar
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Tania Sabroe
Ms. Tania Sabroe
Executive Vice President - People, Organisation & Corporate Affairs
Executive Vice President - People, Organisation & Corporate Affairs
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research & Development
Executive Vice President, Chief Scientific Officer, Research & Development
--
--
Mr. Andreas Fibig
Mr. Andreas Fibig
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Total GLP-1
5.58B
50.68%
Long-acting insulin
759.51M
6.90%
Fast-acting insulin
712.15M
6.47%
Rare blood disorders
411.75M
3.74%
Premix insulin
396.53M
3.60%
其他
3.15B
28.61%
地區USD
名稱
營收
佔比
USA
6.25B
56.75%
Canada
2.08B
18.91%
Emerging Markets
1.24B
11.26%
Region China
792.49M
7.20%
APAC
647.58M
5.88%
業務
地區
業務USD
名稱
營收
佔比
Total GLP-1
5.58B
50.68%
Long-acting insulin
759.51M
6.90%
Fast-acting insulin
712.15M
6.47%
Rare blood disorders
411.75M
3.74%
Premix insulin
396.53M
3.60%
其他
3.15B
28.61%
股東統計
更新時間: 8月30日 週六
更新時間: 8月30日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Jennison Associates LLC
0.56%
Fidelity Management & Research Company LLC
0.38%
Loomis, Sayles & Company, L.P.
0.37%
Capital International Investors
0.35%
Fisher Investments
0.33%
其他
98.01%
持股股東
持股股東
佔比
Jennison Associates LLC
0.56%
Fidelity Management & Research Company LLC
0.38%
Loomis, Sayles & Company, L.P.
0.37%
Capital International Investors
0.35%
Fisher Investments
0.33%
其他
98.01%
股東類型
持股股東
佔比
Investment Advisor
4.84%
Investment Advisor/Hedge Fund
2.60%
Research Firm
0.82%
Hedge Fund
0.41%
Pension Fund
0.32%
Insurance Company
0.19%
Bank and Trust
0.16%
Family Office
0.02%
Family Office
0.02%
其他
90.63%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
2754
330.35M
9.82%
-31.19M
2025Q1
2769
336.08M
9.99%
-21.71M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
2023Q2
1692
293.83M
8.50%
+768.69K
2023Q1
1603
284.38M
8.30%
-15.92M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Jennison Associates LLC
18.82M
0.56%
-1.12M
-5.63%
Mar 31, 2025
Fidelity Management & Research Company LLC
8.98M
0.27%
-907.73K
-9.18%
Mar 31, 2025
Loomis, Sayles & Company, L.P.
12.39M
0.37%
+816.56K
+7.06%
Mar 31, 2025
Capital International Investors
9.51M
0.28%
+2.76M
+40.82%
Mar 31, 2025
Fisher Investments
11.87M
0.35%
-769.25K
-6.09%
Mar 31, 2025
Fayez Sarofim & Co.
11.21M
0.33%
-171.98K
-1.51%
Mar 31, 2025
Folketrygdfondet
9.52M
0.28%
+617.97K
+6.94%
Mar 31, 2025
Managed Account Advisors LLC
8.61M
0.26%
-774.82K
-8.25%
Mar 31, 2025
ClearBridge Investments, LLC
6.63M
0.2%
+2.35M
+54.88%
Mar 31, 2025
Everett Harris & Co.
6.41M
0.19%
-45.07K
-0.70%
Mar 31, 2025
查看更多
持股ETF
更新時間: 9月6日 週六
更新時間: 9月6日 週六
機構名稱
佔比
Defiance Daily Target 2X Long NVO ETF
97.04%
The Opal International Dividend Income ETF
4.59%
GMO International Quality ETF
3.42%
Freedom Day Dividend ETF
1.04%
Amplify International Enhanced Dividend Income ETF
0.69%
Avantis Responsible International Equity ETF
0.43%
Goldman Sachs Innovate Equity ETF
0.36%
Fidelity New Millennium ETF
0.25%
Avantis International Large Cap Value ETF
0.12%
DFA Dimensional Internatl High Profitability ETF
0.07%
查看更多
Defiance Daily Target 2X Long NVO ETF
佔比97.04%
The Opal International Dividend Income ETF
佔比4.59%
GMO International Quality ETF
佔比3.42%
Freedom Day Dividend ETF
佔比1.04%
Amplify International Enhanced Dividend Income ETF
佔比0.69%
Avantis Responsible International Equity ETF
佔比0.43%
Goldman Sachs Innovate Equity ETF
佔比0.36%
Fidelity New Millennium ETF
佔比0.25%
Avantis International Large Cap Value ETF
佔比0.12%
DFA Dimensional Internatl High Profitability ETF
佔比0.07%
分紅派息
近5年累計派現
21.09B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Final Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Interim Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Final Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Final Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Interim Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
Aug 06, 2020
NVO.NB Final Cash Dividend of gross USD 0.517777 paid on Aug 25, 2020 going ex on Aug 14, 2020
Aug 17, 2020
Aug 25, 2020
Aug 14, 2020
Feb 06, 2020
NVO.NB Interim Cash Dividend of gross USD 0.782605 paid on Apr 07, 2020 going ex on Mar 27, 2020
Mar 30, 2020
Apr 07, 2020
Mar 27, 2020
拆合股
公告日期
類型
比率
Aug 14, 2023
Split
1→2
公告日期
類型
比率
Aug 14, 2023
Split
1→2
